Brief: Genscript Biotech Says Probio Nanjing Agrees To Grant To Lanova An Exclusive License For Anti-Pd-1 Single Domain Antibodies
15/11/2024 01:29
Nov 15 (Reuters) - Genscript Biotech Corp 1548.HK :
* PROBIO NANJING AGREES TO GRANT TO LANOVA AN EXCLUSIVE
LICENSE
FOR ANTI-PD-1 SINGLE DOMAIN ANTIBODIES
Further company coverage: 1548.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genscript Biotech
See all newsBrief: Genscript Launches Life Sciences Startup Pitchfest With Nvidia For Biotech Innovation
GenScript Biotech extends gain to hit near 5-year peak on Eli Lilly deal
GenScript Biotech hits near 5-year high on Eli Lilly collaboration
Brief: ProBio & Kun Tuo Announce Strategic Collaboration To Deliver Integrated CDMO-CRO Solutions
HK-listed GenScript Biotech drops on discounted share sale